Accenture (NYSE: ACN) has been positioned as a “Leader” in IDC Health Insights' recently published report, “IDC MarketScape: Worldwide Life Sciences Drug Safety Services 2013 Vendor Assessment.” 1 The report contains a vendor assessment – derived from both qualitative and quantitative metrics as well as end-user feedback – of drug safety service providers in the life sciences industry through the IDC MarketScape model. Click here for a link to the report.
IDC Health Insights assessed 10 drug safety service providers for this report, which is designed to evaluate the characteristics of each firm. In naming Accenture as a leader, the report’s author, Alan S. Louie, PhD, Research Director, Clinical Development Strategy and Technology, IDC Health Insights, said: “Accenture’s market-leading revenue in the drug safety services space, solid customer base with both top pharma and emerging life sciences companies, and strong emphasis on IP development makes the company a formidable competitor in drug safety.”
"We believe Accenture's positioning as a leader in this new report is verification of the results we deliver every day to our life sciences’ clients who entrust us with drug safety services," said David Boath, senior managing director and global lead of Accelerated R&D Services for Accenture’s Life Sciences practice. "End-to-end pharmacovigilance is a critical component of our integrated Accelerated R&D services, designed to deliver quality, compliance and efficiency, which helps our clients to industrialize their operations, derive insights and reduce costs, so they can focus on strategic decision making that improves safety for patients around the world.”
The IDC MarketScape divides potential key strategy measures for success into two primary categories: capabilities and strategies. IDC Health Insights specifically noted in this report, “With its performance-based approach options and significant dedication to innovate, it is clear that Accenture has a clear vision and commitment to growth in this area.”
IDC Health Insights focuses on the following key criteria in defining excellence in drug safety services:
- Service focus experience (i.e., BPO, IT services, or strategic consulting services)
- Breadth of service offerings (supporting BPO)
- Diversity of resources and infrastructure supporting services delivery
- Project experience in the life science Drug Safety Services outsourcing market
- Strength of project leaders and their teams
- Quality of work and customer satisfaction
1 IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment, doc #HI239221, February 2013. Click here to access the full report.
Accenture is a global management consulting, technology services and outsourcing company, with approximately 261,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$27.9 billion for the fiscal year ended Aug. 31, 2012. Its home page is www.accenture.com.
About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of IT, telecommunications, or industry-specific suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT, telecommunications, or industry-specific vendors can be meaningfully compared. The framework also provides technology buyers with a transparent foundation to allow companies to independently compare the strengths and weaknesses of current and prospective vendors.